新型口服抗凝药物的研究进展  

Research Advances in New Oral Anticoagulants

作　　者：何改平[1] 张彬[1] 

机构地区：[1]天津市第四医院脑系科,天津300222

出　　处：《医学综述》2015年第8期1432-1435,共4页Medical Recapitulate

摘　　要：新型口服抗凝药物(NOAC)通过凝血酶(达比加群酯)或凝血因子Xa(利伐沙班和阿哌沙班)途径预防和治疗血栓。与维生素K抑制剂(如华法林)比较,NOAC优势明显,起效快、代谢迅速、药物相互作用少、药动学预测性好、不需要常规监测凝血功能。近期临床试验证实了NOAC预防心房颤动患者卒中和栓塞、骨科手术后静脉血栓栓塞症的安全性和有效性。The new oral anticoagulants（NOAC） target on either thrombin（dabigatran etexilate） or clot-ting factor Xa （ rivaroxaban and apixaban ） for the prevention and treatment of thrombosis .Compared with vitamin K inhibitors （ such as warfarin ） , NOAC have pharmacologic advantages of rapid onset/offset of action,few drug interactions,predictable pharmacokinetics,and no requirement for regular coagulation moni-toring.Recent clinical trials have demonstrated the efficacy and safety of NOAC in preventing and treating stroke in patients with atrial fibrillation and venous thromboembolism as well as venous thromboembolism in patients after hip or knee arthroplasty .

关 键 词：新型口服抗凝药物 华法林 心房颤动 血栓栓塞 

分 类 号：R972[医药卫生—药品]